Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.64 |
| ▸ | DRD4 | P21917 | 11/20 | 0.64 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.60 |
| ▸ | CCR3 | P51677 | 5/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.54 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.54 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.53 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5258356 | 1.00 | DRD2 (0.64) | DRD2DRD4MCHR1CCR3HTR2A | |
| SCHEMBL5263219 | 0.88 | L3MBTL1 (0.64) | DRD2DRD4CCR3HTR2AHDAC3 | |
| SCHEMBL5263211 | 0.88 | L3MBTL1 (0.64) | DRD2DRD4CCR3HTR2AHDAC3 | |
| SCHEMBL5258054 | 0.86 | CCR3 (0.62) | DRD2DRD4MCHR1CCR3HTR2A | |
| SCHEMBL5258050 | 0.86 | CCR3 (0.62) | DRD2DRD4MCHR1CCR3HTR2A | |
| SCHEMBL5258609 | 0.86 | DRD2 (0.64) | DRD2DRD4HTR2A | |
| SCHEMBL5258616 | 0.86 | DRD2 (0.64) | DRD2DRD4HTR2A | |
| SCHEMBL5255698 | 0.85 | CCR2 (0.65) | DRD2DRD4HTR2A | |
| SCHEMBL5255707 | 0.85 | CCR2 (0.65) | DRD2DRD4HTR2A | |
| SCHEMBL5257924 | 0.84 | DRD2 (0.66) | DRD2DRD4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1496896-A4 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2007-10-31 | — | — | EP | claimed |
| US-7223738-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-05-29 | — | — | US | claimed |
| US-20050222155-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2005-10-06 | — | — | US | claimed |
| EP-1496896-A1 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | claimed |
| WO-2003086394-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | claimed |
| EP-1496896-A4 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2007-10-31 | — | — | EP | disclosed |
| US-7223738-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223738-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223738-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050222155-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2005-10-06 | — | — | US | disclosed |
| EP-1496896-A1 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003086394-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222155-A1 | Inhibitors of akt activity | AKT1, AKT2, AKT3 | DRD2 4437/4885DRD4 4245/4885MCHR1 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.